• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by MiMedx Group Inc

    11/7/24 10:25:58 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email
    SC 13G 1 tm2427429d1_sc13g.htm SC 13G

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE
    COMMISSION
     
      Washington, D.C. 20549  

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    Information Statement Pursuant to Rules 13d-1

    Under the Securities Exchange Act of 1934
    (Amendment No.)*

     

    MIMEDX GROUP, INC.

    (Name of Issuer)

     

    Common Stock, Par Value of $0.001 Per Share

    (Title of Class of Securities)

     

    602496101

    (CUSIP Number)

     

    August 30. 2024

    Date of Event Which Requires Filing of the Statement

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 602496101Schedule 13GPage 2 of 12

     

      1. Name of Reporting Person
    S.S. or I.R.S. Identification No. of Above Person
    Trigran Investments, Inc.
     
      2. Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Illinois corporation
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,362,292 shares of common stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,690,369 shares of common stock
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,690,369 shares of common stock (1)
     
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    Approximately 5.2% (based on 146,946,213 shares of common stock issued and outstanding as of October 21, 2024, pursuant to the MiMedx Group, Inc. Form 10-Q filed with the SEC on October 30, 2024)
     
      12. Type of Reporting Person
    IA/CO
               

    (1)   The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.

     

    CUSIP No. 602496101Schedule 13GPage 3 of 12

     

      1. Name of Reporting Person
    S.S. or I.R.S. Identification No. of Above Person
    Douglas Granat
     
      2. Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    U.S. Citizen
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,362,292 shares of common stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,690,369 shares of common stock
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,690,369 shares of common stock (1)
     
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    Approximately 5.2% (based on 146,946,213 shares of common stock issued and outstanding as of October 21, 2024, pursuant to the MiMedx Group, Inc. Form 10-Q filed with the SEC on October 30, 2024)
     
      12. Type of Reporting Person
    IN/HC
               

    (1)  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of his pecuniary interest.

     

    CUSIP No. 602496101Schedule 13GPage 4 of 12

     

      1. Name of Reporting Person
    S.S. or I.R.S. Identification No. of Above Person
    Lawrence A. Oberman
     
      2. Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    U.S. Citizen
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,362,292 shares of common stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,690,369 shares of common stock
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,690,369 shares of common stock (1)
     
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    Approximately 5.2% (based on 146,946,213 shares of common stock issued and outstanding as of October 21, 2024, pursuant to the MiMedx Group, Inc. Form 10-Q filed with the SEC on October 30, 2024)
     
      12. Type of Reporting Person
    IN/HC
               

    (1)  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of his pecuniary interest.

     

    CUSIP No. 602496101Schedule 13GPage 5 of 12

     

      1. Name of Reporting Person
    S.S. or I.R.S. Identification No. of Above Person
    Steven G. Simon
     
      2. Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    U.S. Citizen
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,362,292 shares of common stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,690,369 shares of common stock
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,690,369 shares of common stock (1)
     
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    Approximately 5.2% (based on 146,946,213 shares of common stock issued and outstanding as of October 21, 2024, pursuant to the MiMedx Group, Inc. Form 10-Q filed with the SEC on October 30, 2024)
     
      12. Type of Reporting Person
    IN/HC
               

    (1)  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of his pecuniary interest.

     

    CUSIP No. 602496101Schedule 13GPage 6 of 12

     

      1. Name of Reporting Person
    S.S. or I.R.S. Identification No. of Above Person
    Bradley F. Simon
     
      2. Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    U.S. Citizen
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,362,292 shares of common stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,690,369 shares of common stock
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,690,369 shares of common stock (1)
     
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    Approximately 5.2% (based on 146,946,213 shares of common stock issued and outstanding as of October 21, 2024, pursuant to the MiMedx Group, Inc. Form 10-Q filed with the SEC on October 30, 2024)
     
      12. Type of Reporting Person
    IN/HC
               

    (1)  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of his pecuniary interest.

     

    CUSIP No. 602496101Schedule 13GPage 7 of 12

     

      1. Name of Reporting Person
    S.S. or I.R.S. Identification No. of Above Person
    Steven R. Monieson
     
      2. Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) x
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    U.S. Citizen
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
    7,362,292 shares of common stock
     
    7. Sole Dispositive Power
    0
     
    8. Shared Dispositive Power
    7,690,369 shares of common stock
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    7,690,369 shares of common stock (1)
     
      10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    Approximately 5.2% (based on 146,946,213 shares of common stock issued and outstanding as of October 21, 2024, pursuant to the MiMedx Group, Inc. Form 10-Q filed with the SEC on October 30, 2024)
     
      12. Type of Reporting Person
    IN/HC
               

    (1)  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of his pecuniary interest.

     

    CUSIP No. 602496101Schedule 13GPage 8 of 12

     

    Item 1(a) Name of Issuer:
    MiMedx Group, Inc.
    Item 1(b) Address of Issuer’s Principal Executive Offices:
    1775 West Oak Commons Court, NE
    Marietta, GA 30062
     
    Item 2(a) Name of Person Filing
    See Item 2(c)
    Item 2(b) Address of Principal Business Office
    See Item 2(c)
    Item 2(c)

    Citizenship
    Trigran Investments, Inc.
    630 Dundee Road, Suite 230
    Northbrook, IL 60062
    Illinois corporation

     

    Douglas Granat
    630 Dundee Road, Suite 230
    Northbrook, IL 60062
    U.S. Citizen 

     

    Lawrence A. Oberman
    630 Dundee Road, Suite 230
    Northbrook, IL 60062
    U.S. Citizen 

     

    Steven G. Simon
    630 Dundee Road, Suite 230
    Northbrook, IL 60062
    U.S. Citizen

     

    Bradley F. Simon
    630 Dundee Road, Suite 230
    Northbrook, Illinois 60062
    U.S. Citizen

     

    Steven R. Monieson
    630 Dundee Road, Suite 230
    Northbrook, Illinois 60062

    U.S. Citizen

    Item 2(d) Title of Class of Securities:
    Common Stock, par value of $0.001 per share
    Item 2(e) CUSIP Number:
    602496101

     

    Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
      (a) ¨ Broker or dealer registered under section 15 of the Exchange Act;
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act;

     

    CUSIP No. 602496101Schedule 13GPage 9 of 12

     

      (c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act;
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act;
           
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act;
           
      (j) ¨ A non-U.S. institution in accordance with Rule 13d–1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d–1(b)(1)(ii)(J), please specify the type of institution:______________

     

    If this statement is filed pursuant to Rule 13d-1(c), check this box. ¨

     

    Item 4 Ownership:(2)
      (a) Amount beneficially owned:
    Incorporated by reference to Item 9 of the cover page pertaining to each reporting person.
      (b) Percent of class:
    Incorporated by reference to Item 11 of the cover page pertaining to each reporting person.
      (c)

    Number of shares as to which such person has:

     

        (i)

    Sole power to vote or to direct the vote:

    Incorporated by reference to Item 5 of the cover page pertaining to each reporting person.

        (ii)

    Shared power to vote or to direct the vote:

    Incorporated by reference to Item 6 of the cover page pertaining to each reporting person.

        (iii)

    Sole power to dispose or to direct the disposition of:

    Incorporated by reference to Item 7 of the cover page pertaining to each reporting person.

        (iv)

    Shared power to dispose or to direct the disposition of:

    Incorporated by reference to Item 8 of the cover page pertaining to each reporting person.

     

    (2)  Douglas Granat, Lawrence A. Oberman, Steven G. Simon, Bradley F. Simon, and Steven R. Monieson are the controlling shareholders and officers of Trigran Investments, Inc. and thus may be considered the beneficial owners of shares beneficially owned by Trigran Investments, Inc.

     

    CUSIP No. 602496101Schedule 13GPage 10 of 12

     

    Item 5 Ownership of Five Percent or Less of a Class:
      Not Applicable.
     
    Item 6 Ownership of More than Five Percent on Behalf of Another Person:
      Not Applicable.
     
    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
      Not Applicable.
     
    Item 8 Identification and Classification of Members of the Group:
      Not Applicable.
     
    Item 9 Notice of Dissolution of Group:
      Not Applicable.

     

    Item 10 Certification:
     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 602496101Schedule 13GPage 11 of 12

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned Reporting Persons certify that the information set forth in this statement is true, complete, and correct.

     

    Date: November 7, 2024

     

    TRIGRAN INVESTMENTS, INC.  
       
    By: /s/ Lawrence A. Oberman  
    Name: Lawrence A. Oberman  
    Title: Executive Vice President  
       
    /s/ Douglas Granat  
    Douglas Granat  
       
    /s/ Lawrence A. Oberman  
    Lawrence A. Oberman  
       
    /s/ Steven G. Simon  
    Steven G. Simon  
       
    /s/ Bradley F. Simon  
    Bradley F. Simon  
       
    /s/ Steven R. Monieson  
    Steven R. Monieson  

     

    CUSIP No. 602496101Schedule 13GPage 12 of 12

     

    INDEX TO EXHIBITS

     

      PAGE
       
    EXHIBIT 1: Agreement to Make a Joint Filing 1

     

     

     

    Get the next $MDXG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDXG

    DatePrice TargetRatingAnalyst
    7/2/2024$11.00Overweight
    Cantor Fitzgerald
    3/7/2024$12.00Buy
    Lake Street
    10/27/2023$12.00Buy
    Craig Hallum
    10/13/2022$7.00Buy
    Mizuho
    9/14/2021$20.00 → $8.50Buy
    HC Wainwright & Co.
    7/26/2021$23.00Outperform
    Northland Capital
    More analyst ratings

    $MDXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

    Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year  Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are proud to report on the Company's outst

    7/30/25 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

    MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") and Vaporox, Inc. ("Vaporox") today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions. Vaporox is a privately held, Denver-based company that has developed and is commercializing its patented Vaporous Hyperoxia Therapy ("VHT") device for treating chronic and hard-to-heal wounds. VHT delivers two healing modalities, ultrasonic mist and concentrated oxygen, in a

    7/30/25 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30

    MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on Wednesday, July 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13754722 A replay of the webcast will be available for approximately 30 days on the Company's website

    7/16/25 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    SEC Filings

    View All

    MiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MIMEDX GROUP, INC. (0001376339) (Filer)

    7/30/25 4:03:53 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by MiMedx Group Inc

    10-Q - MIMEDX GROUP, INC. (0001376339) (Filer)

    7/30/25 4:01:02 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by MiMedx Group Inc

    S-8 - MIMEDX GROUP, INC. (0001376339) (Filer)

    7/28/25 4:25:39 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    5/5/25 10:06:51 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    11/22/23 5:01:18 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on MiMedx Group with a new price target

    Cantor Fitzgerald initiated coverage of MiMedx Group with a rating of Overweight and set a new price target of $11.00

    7/2/24 7:38:13 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on MiMedx Group with a new price target

    Lake Street initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

    3/7/24 8:26:30 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on MiMedx Group with a new price target

    Craig Hallum initiated coverage of MiMedx Group with a rating of Buy and set a new price target of $12.00

    10/27/23 9:04:53 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Doug Rice covered exercise/tax liability with 12,749 shares, decreasing direct ownership by 6% to 188,024 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    7/7/25 5:59:59 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 12,034 shares, decreasing direct ownership by 4% to 295,282 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    6/26/25 4:48:44 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Newton Todd was granted 28,609 shares, increasing direct ownership by 7% to 412,771 units (SEC Form 4)

    4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

    6/23/25 6:46:57 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Leadership Updates

    Live Leadership Updates

    View All

    Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

    Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

    7/17/24 8:00:00 AM ET
    $MDXG
    $SAVA
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer

    MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020. "I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Under Kim's leadership as SVP of Sales for the past four years, the MIMEDX commercial organization has navigated significant change and has been transformed into the high-performing team we have today. As we continue to work our way through a period of swe

    6/26/24 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces Appointment of Two New Independent Directors

    MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors. M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, "On behalf of the entire Board of Directors, we are honored to welcome these a

    3/4/24 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/12/24 4:04:33 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MiMedx Group Inc

    SC 13G - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/7/24 10:25:58 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MiMedx Group Inc

    SC 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)

    11/4/24 1:30:50 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDXG
    Financials

    Live finance-specific insights

    View All

    MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

    Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year  Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are proud to report on the Company's outst

    7/30/25 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30

    MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on Wednesday, July 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13754722 A replay of the webcast will be available for approximately 30 days on the Company's website

    7/16/25 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MIMEDX Announces First Quarter 2025 Operating and Financial Results

    Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2025. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "Our solid first quarter 2025 results include total

    4/30/25 4:01:00 PM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care